MeiraGTx rises on positive data from genetic eye condition treatment

MeiraGTx Holdings

21/02/2025 14:01

** Shares of gene therapy company MeiraGTx Holdings plc
 MGTX.O  up 13.6% at $7.76 premarket 
        ** Co says 
    early-stage study
     data for its experimental gene therapy, rAAV8.hRKp.AIPL1,
showed safety, efficacy and meaningful responses for treatment
of genetic eye condition called retinal dystrophy 
  
        ** Says children who were blind at birth were treated
with the gene therapy and showed visual acuity in eyes after
four or more weeks in small study
  
    ** The therapy showed improved functional vision and
evidence of protection against progressive retinal degeneration,
without serious adverse effects
    ** Retinal dystrophy is caused due to genetic deficiency of
type of protein called AIPL1, which leads severe impairment of
sight from birth
    ** Co says study data is published in medical journal The
Lancet
        ** MGTX stock has risen ~16% in last 12 months
  

 (Reporting by Siddhi Mahatole)
 ((Siddhiprabhanjan.mahatole@thomsonreuters.com))